Primary Sclerosing Cholangitis: Is any treatment worthwhile?

被引：12
作者：
Ashley Barnabas
Roger W. Chapman
机构：
[1] Translational Gastroenterology Unit, John Radcliffe Hospital, Oxford OX3 9DU, Headley Way
来源：
Current Gastroenterology Reports | 2012年 / 14卷 / 1期
关键词：
Antibiotics; Autoimmune hepatitis/PSC overlap; Hepatic osteodystrophy; Liver transplantation; Nuclear hormone receptor antagonists; Primary sclerosing cholangitis; PSC with autoimmune features; PSC-IBD; Ursodeoxycholic acid;
D O I：
10.1007/s11894-011-0230-8
中图分类号：
学科分类号：
摘要：
While many therapeutic agents have been evaluated in Primary Sclerosing Cholangitis (PSC), none have been shown in controlled trials to modify the course of disease. The bile acid ursodeoxycholic acid (UDCA) has been widely used in the treatment of PSC but its use remains controversial. It may have a role in providing chemoprotection against the development of colonic dysplasia/cancer in patients with associated inflammatory bowel disease. The exclusion of IgG4-associated cholangitis, which generally responds to immunosuppressant agents, is essential prior to deciding on an appropriate therapeutic strategy in PSC. In the absence of proven therapeutic agents, treatment strategies are usually aimed at minimizing the complications of the biliary disease. Endoscopic management of dominant strictures may improve long-term outcomes. Orthotopic liver transplantation has a good outcome in patients with end stage PSC. © 2011 Springer Science+Business Media, LLC.
引用
收藏
页码：17 / 24
页数：7
相关论文
共 56 条
[1]  
Maggs J.R.L., Chapman R.W., An update on primary sclerosing cholangitis, Current Opinion in Gastroenterology, 24, 3, pp. 377-383, (2008)
[2]  
Loftus Jr. E.V., Harewood G.C., Loftus C.G., Tremaine W.J., Harmsen W.S., Zinsmeister A.R., Jewell D.A., Sandborn W.J., PSC-IBD: A unique form of inflammatory bowel disease associated with primary sclerosing cholangitis, Gut, 54, 1, pp. 91-96, (2005)
[3]  
Chari S.T., Diagnosis of autoimmune pancreatitis using its five cardinal features: Introducing the Mayo Clinic's HISORt criteria, Journal of Gastroenterology, 42, SUPPL. 18, pp. 39-41, (2007)
[4]  
Lee J., Belanger A., Doucette J.T., Stanca C., Friedman S., Bach N., Transplantation Trends in Primary Biliary Cirrhosis, Clinical Gastroenterology and Hepatology, 5, 11, pp. 1313-1315, (2007)
[5]  
Stanich P.P., Bjornsson E., Lindor K.D., Et al., Alkaline phosphatase normalization is associated with better prognosis in primary sclerosing cholangitis, Dig Liver Dis., 43, 4, pp. 309-313, (2011)
[6]  
Paumgartner G., Beuers U., Ursodeoxycholic acid in cholestatic liver disease: Mechanisms of action and therapeutic use revisited, Hepatology, 36, 3, pp. 525-531, (2002)
[7]  
Lindor K.D., Ursodiol for primary sclerosing cholangitis, New England Journal of Medicine, 336, 10, pp. 691-695, (1997)
[8]  
Mitchell S.A., Bansi D.S., Hunt N., Von Bergmann K., Fleming K.A., Chapman R.W., A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis, Gastroenterology, 121, 4, pp. 900-907, (2001)
[9]  
Olsson R., Boberg K.M., Schaffalitsky De Muckadell O., Lindgren S., Hultcrantz R., Folvik G., Bell H., Gangsoy-Kristiansen M., Matre J., Rydning A., Wikman O., Danielsson A., Sandberg-Gertzen H., Ung K.-A., Eriksson A., Loof L., Prytz H., Marschall H.-U., Broome U., High-dose ursodeoxycholic acid in primary sclerosing cholangitis: A 5-year multicenter, randomized, controlled study, Gastroenterology, 129, 5, pp. 1464-1472, (2005)
[10]  
Lindor K.D., Kowdley K.V., Luketic V.A., Et al., High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis, Hepatology, 50, 3, pp. 808-814, (2009)
123456